Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials.Annals of oncology : official journal of the European Society for Medical Oncology · 2025Trial
- Brachytherapy monotherapy for favorable and select unfavorable intermediate risk prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Long-Term Outcomes of Low-Dose-Rate Brachytherapy in Localized Prostate Cancer: A 17-Year Retrospective Analysis of a Single-Center Portuguese Cohort.Journal of clinical medicine · 2026Article
- Permanent seed brachytherapy for prostate cancer: Monotherapy, combined, and salvage approaches remain effective and well-tolerated options.Journal of contemporary brachytherapy · 2026Article
- Genitourinary Toxicity, Function, and Quality of Life in Patients Undergoing Prostate Radiation Therapy-A Scoping Review.Lower urinary tract symptoms · 2026Article
- Amplifying radiation-induced anti-tumor immunity: the dual role of brachytherapy and low-dose total body irradiation.Frontiers in immunology · 2026Article
- Brachytherapy as a Cancer Therapy Tool.Journal of cancer education : the official journal of the American Association for Cancer Education · 2025Review
- High-Dose-Rate Brachytherapy Boost for Prostate Cancer: A Retrospective Observational Study in Low- and Middle-Income Countries.Advances in radiation oncology · 2025Article
- The Early Detection, Diagnostic Evaluation, and Local Treatment of Prostate Cancer: A Paradigm Shift.Deutsches Arzteblatt international · 2025Review
- Predicting intermediate-risk prostate cancer using machine learning.International urology and nephrology · 2025Article
- Orchiepididymitis as a rare complication of TURP performed four weeks after high-dose-rate brachytherapy for prostate cancer.Journal of contemporary brachytherapy · 2025Article
- High-dose-rate brachytherapy lowers travel burden for men with localized prostate cancer compared with external beam radiation.Frontiers in urology · 2025Article
- Biochemical control in intermediate- and high-risk prostate cancer after EBRT with and without brachytherapy boost.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Complications leading to hospitalisation 12 months after brachytherapy or high-intensity focused ultrasound for localized prostate cancer: French national from the PMSI-MCO data, 2019 and 2020.Clinical and translational radiation oncology · 2024Article
- Overall Survival and Cancer-Specific Mortality in Patients with Prostate Cancer Undergoing Definitive Therapies: A Narrative Review.Journal of clinical medicine · 2024Review
- The expanding role of radiation oncology across the prostate cancer continuum.Abdominal radiology (New York) · 2024Review
- Impact of androgen deprivation therapy in patients with unfavorable intermediate-risk prostate cancer receiving brachytherapy-based dose-escalated radiation therapy.Journal of contemporary brachytherapy · 2024Article
- Quantitative PSMA-PET parameters in localized prostate cancer: prognostic and potential predictive value.Radiation oncology (London, England) · 2024Article
- Palladium-103 (Theranostics · 2024Article
- Ultra-low dose rate brachytherapy (uLDR-BT) in treatment of patients with unfavorable intermediate-risk group prostate cancer - retrospective analysis.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 16 institutions in 2 countries.
Funding
Abstract
purposeTo determine whether addition of external beam radiation therapy (EBRT) to brachytherapy (BT) (COMBO) compared with BT alone would improve 5-year freedom from progression (FFP) in intermediate-risk prostate cancer.
methodsMen with prostate cancer stage cT1c-T2bN0M0, Gleason Score (GS) 2-6 and prostate-specific antigen (PSA) 10-20 or GS 7, and PSA < 10 were eligible. The COMBO arm was EBRT (45 Gy in 25 fractions) to prostate and seminal vesicles followed by BT prostate boost (110 Gy if 125-Iodine, 100 Gy if 103-Pd). BT arm was delivered to prostate only (145 Gy if 125-Iodine, 125 Gy if 103-Pd). The primary end point was FFP: PSA failure (American Society for Therapeutic Radiology and Oncology [ASTRO] or Phoenix definitions), local failure, distant failure, or death.
resultsFive hundred eighty-eight men were randomly assigned; 579 were eligible: 287 and 292 in COMBO and BT arms, respectively. The median age was 67 years; 89.1% had PSA < 10 ng/mL, 89.1% had GS 7, and 66.7% had T1 disease. There were no differences in FFP. The 5-year FFP-ASTRO was 85.6% (95% CI, 81.4 to 89.7) with COMBO compared with 82.7% (95% CI, 78.3 to 87.1) with BT (odds ratio [OR], 0.80; 95% CI, 0.51 to 1.26; Greenwood T
conclusionCompared with BT, COMBO did not improve FFP for prostate cancer but caused greater toxicity. BT alone can be considered as a standard treatment for men with intermediate-risk prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.